Addition of VX-661 to KALYDECO® (ivacaftor) Improves Lung Function in People with CF Who Are Heterozygous for the F508del and G551D Mutations in 28-day Phase 2 Proof-of-Concept Study -Data provide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback